{"id":"pf-07321332","rwe":[{"pmid":"41558303","year":"2026","title":"Absorption, distribution, metabolism, and excretion tactics toward the expedited discovery and development of the severe acute respiratory syndrome coronavirus-2 main protease inhibitor nirmatrelvir.","finding":"","journal":"Drug metabolism and disposition: the biological fate of chemicals","studyType":"Clinical Study"},{"pmid":"41203702","year":"2025","title":"Insights from integrated covalent docking and molecular dynamics simulations of nirmatrelvir analogs as potential SARS-CoV-2 M(pro) inhibitors.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"40220677","year":"2025","title":"Silaproline-bearing nirmatrelvir derivatives are potent inhibitors of the SARS-CoV-2 main protease highlighting the value of silicon-derivatives in structure-activity-relationship studies.","finding":"","journal":"European journal of medicinal chemistry","studyType":"Clinical Study"},{"pmid":"40152255","year":"2025","title":"The Sprint to Develop Coronavirus Antivirals.","finding":"","journal":"Journal of medicinal chemistry","studyType":"Clinical Study"},{"pmid":"35073029","year":"2006","title":"Nirmatrelvir.","finding":"","journal":"","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"J05AE30","category":"atc"},{"label":"Active","category":"status"},{"label":"COVID-19","category":"indication"},{"label":"Pfizer, Inc.","category":"company"},{"label":"Approved 2020s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protease Inhibitors","category":"pharmacology"},{"label":"Viral Protease Inhibitors","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":160.74,"date":"","count":54,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 54 times (LLR=161)"},{"llr":111.66,"date":"","count":44,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 44 times (LLR=112)"},{"llr":102.258,"date":"","count":39,"signal":"Toxicity to various agents","source":"DrugCentral FAERS","actionTaken":"Reported 39 times (LLR=102)"}],"commonSideEffects":[],"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Pfizer","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2041-10-31","territory":"US","patentNumber":"11541034"},{"source":"FDA Orange Book via DrugCentral","expires":"2041-08-05","territory":"US","patentNumber":"11351149"}],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:04:44.441981+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:04:52.906276+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5432119/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:04:38.516157+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:04:54.242540+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:04:36.722637+00:00"},"recentPublications":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:04:37.728229+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:04:54.242513+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:04:54.242505+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:04:54.242403+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:04:54.242432+00:00"}},"allNames":"paxlovid (copackaged)","offLabel":[],"synonyms":["nirmatrelvir","paxlovid","PF-07321332"],"timeline":[{"date":"2022-01-28","type":"positive","source":"DrugCentral","milestone":"EMA approval (Pfizer Europe MA EEIG)"},{"date":"2022-02-10","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Pfizer Japan Inc)"},{"date":"2023-05-25","type":"positive","source":"DrugCentral","milestone":"FDA approval (Pfizer, Inc.)"}],"aiSummary":"Paxlovid, developed by Pfizer, holds a dominant market position as one of the leading antiviral treatments for COVID-19, with potential to be the world's best-selling drug. Its competitive advantage lies in its mechanism of action, which effectively inhibits the viral replication enzyme essential for SARS-CoV-2. A key risk is the presence of strong competition from other protease inhibitors such as saquinavir, indinavir, ritonavir, nelfinavir, and amprenavir. Despite having no ongoing clinical trials, Paxlovid's future pipeline outlook remains robust, supported by its approved indication and the potential for expanded use through PD-L1 companion diagnostics.","brandName":"Paxlovid (Copackaged)","ecosystem":[{"indication":"COVID-19","otherDrugs":[{"name":"bamlanivimab","slug":"bamlanivimab","company":"Eli Lilly and Company"},{"name":"casirivimab","slug":"casirivimab","company":"Regeneron Pharmaceuticals, Inc."},{"name":"etesevimab","slug":"etesevimab","company":"Eli Lilly and Company"},{"name":"imdevimab","slug":"imdevimab","company":"Regeneron Pharmaceuticals, Inc."}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","explanation":"Think of it like a key that fits into a lock. The SARS-CoV-2 virus has a special enzyme that it needs to make copies of itself, and Paxlovid is like a key that blocks that enzyme from working. This helps to slow down the spread of the virus in the body.","oneSentence":"Paxlovid works by inhibiting the activity of an enzyme that the SARS-CoV-2 virus needs to replicate.","technicalDetail":"Paxlovid is a protease inhibitor that targets the SARS-CoV-2 main protease (Mpro), preventing the virus from processing its polyprotein into functional subunits necessary for replication and transcription."},"chemblData":{"prodrug":-1,"chemblId":"CHEMBL5432119","maxPhase":null,"chirality":-1,"parenteral":false,"availability":-1,"moleculeType":null,"withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"fdaRecalls":[],"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5520","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=pf-07321332","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07321332","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T01:52:53.069418","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-19T23:04:52.906360+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"saquinavir","drugSlug":"saquinavir","fdaApproval":"1995-12-06","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"indinavir","drugSlug":"indinavir","fdaApproval":"1996-03-13","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ritonavir","drugSlug":"ritonavir","fdaApproval":"1996-03-01","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nelfinavir","drugSlug":"nelfinavir","fdaApproval":"1997-03-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"amprenavir","drugSlug":"amprenavir","fdaApproval":"1999-04-15","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"fosamprenavir","drugSlug":"fosamprenavir","fdaApproval":"2003-10-20","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"atazanavir","drugSlug":"atazanavir","fdaApproval":"2003-06-20","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tipranavir","drugSlug":"tipranavir","fdaApproval":"2005-06-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"darunavir","drugSlug":"darunavir","fdaApproval":"2006-06-23","patentExpiry":"Jun 26, 2027","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"pf-07321332","indications":{"approved":[{"name":"COVID-19","source":"DrugCentral","snomedId":840539006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"saquinavir","brandName":"saquinavir","genericName":"saquinavir","approvalYear":"1995","relationship":"same-class"},{"drugId":"indinavir","brandName":"indinavir","genericName":"indinavir","approvalYear":"1996","relationship":"same-class"},{"drugId":"ritonavir","brandName":"ritonavir","genericName":"ritonavir","approvalYear":"1996","relationship":"same-class"},{"drugId":"nelfinavir","brandName":"nelfinavir","genericName":"nelfinavir","approvalYear":"1997","relationship":"same-class"},{"drugId":"amprenavir","brandName":"amprenavir","genericName":"amprenavir","approvalYear":"1999","relationship":"same-class"},{"drugId":"fosamprenavir","brandName":"fosamprenavir","genericName":"fosamprenavir","approvalYear":"2003","relationship":"same-class"},{"drugId":"atazanavir","brandName":"atazanavir","genericName":"atazanavir","approvalYear":"2003","relationship":"same-class"},{"drugId":"tipranavir","brandName":"tipranavir","genericName":"tipranavir","approvalYear":"2005","relationship":"same-class"},{"drugId":"darunavir","brandName":"darunavir","genericName":"darunavir","approvalYear":"2006","relationship":"same-class"}],"trialDetails":[],"_emaApprovals":[{"date":"2022-01-28","status":"Authorised","company":"Pfizer Europe MA EEIG"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"354383","NDDF":"018919","UNII":"7R9A5P7H32","CHEBI":"CHEBI:170007","VANDF":"4041063","INN_ID":"12161","RXNORM":"2587892","UMLSCUI":"C5545149","chemblId":"CHEMBL5432119","ChEMBL_ID":"CHEMBL4802135","KEGG_DRUG":"D12244","DRUGBANK_ID":"DB16691","PDB_CHEM_ID":" ZGW","PUBCHEM_CID":"155903259","IUPHAR_LIGAND_ID":"11503","MESH_SUPPLEMENTAL_RECORD_UI":"C000718217"},"formularyStatus":[],"_enricherVersion":"v2","chemblMechanisms":[],"developmentCodes":[],"ownershipHistory":[{"period":"2023-","companyName":"Pfizer","relationship":"Original Developer"},{"period":"2022","companyName":"Pfizer Europe MA EEIG","relationship":"EMA Licensee"},{"period":"2022","companyName":"Pfizer Japan Inc","relationship":"PMDA Licensee"}],"publicationCount":84,"therapeuticAreas":["Infectious Disease"],"_revenueScrapedAt":"2026-03-31 14:05:45.012475+00","atcClassification":{"source":"DrugCentral","atcCode":"J05AE30","allCodes":["J05AE30"]},"biosimilarFilings":[],"originalDeveloper":"Pfizer, Inc.","recentPublications":[{"pmid":"40019854","title":"Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease.","authors":"Tuttle JB, Allais C, Allerton CMN, Anderson AS, Arcari JT","journal":"J Med Chem","pubDate":"2025 Apr 10"},{"pmid":"39616543","title":"Molecular dynamic simulations to explore the broad-spectrum activity of the inhibitor PF-07321332 against human coronavirus.","authors":"Liu MT, Wang YT, Li Y, Sang P, Yang LQ","journal":"J Biomol Struct Dyn","pubDate":"2026 Mar"},{"pmid":"38257765","title":"Structural Basis for the Inhibition of SARS-CoV-2 M(pro) D48N Mutant by Shikonin and PF-07321332.","authors":"Zhao Z, Zhu Q, Zhou X, Li W, Yin X","journal":"Viruses","pubDate":"2023 Dec 30"},{"pmid":"36965419","title":"Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332.","authors":"Zhou Y, Wang W, Zeng P, Feng J, Li D","journal":"Biochem Biophys Res Commun","pubDate":"2023 May 21"},{"pmid":"36276807","title":"Total synthesis of antiviral drug, nirmatrelvir (PF-07321332).","authors":"Shekhar C, Nasam R, Paipuri SR, Kumar P, Nayani K","journal":"Tetrahedron Chem","pubDate":"2022 Dec"},{"pmid":"36124909","title":"Structural insights into Nirmatrelvir (PF-07321332)-3C-like SARS-CoV-2 protease complexation: a ligand Gaussian accelerated molecular dynamics study.","authors":"Wang YT, Liao JM, Lin WW, Li CC, Huang BC","journal":"Phys Chem Chem Phys","pubDate":"2022 Sep 28"},{"pmid":"36060104","title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations.","authors":"Joyce RP, Hu VW, Wang J","journal":"Med Chem Res","pubDate":"2022"},{"pmid":"35983623","title":"2D-QSAR, docking, molecular dynamics, studies of PF-07321332 analogues to identify alternative inhibitors against 3CL(pro) enzyme in SARS-CoV disease.","authors":"Bitam S, Hamadache M, Hanini S","journal":"J Biomol Struct Dyn","pubDate":"2023 Aug-Sep"},{"pmid":"35640480","title":"Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the monomer of the main protease SARS-CoV-2: A volumetric study based on molecular dynamics, elastic networks, classical thermodynamics and SPT.","authors":"Alvarado YJ, Olivarez Y, Lossada C, Vera-Villalobos J, Paz JL","journal":"Comput Biol Chem","pubDate":"2022 Aug"},{"pmid":"35505633","title":"PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.","authors":"Hau RK, Wright SH, Cherrington NJ","journal":"Clin Transl Sci","pubDate":"2022 Jul"}],"_revenueClearedDupe":"nirmatrelvir","participantFlowData":[],"companionDiagnostics":[],"structuredTrialResults":[],"genericManufacturerList":[],"status":"discontinued","companyName":"Pfizer","companyId":"pfizer","modality":"Small Molecule","firstApprovalDate":"2023","enrichmentLevel":5,"visitCount":8,"patentsNormalised":[{"patent_number":"11351149","territory":"US","patent_type":null,"expiry_date":"2041-08-05T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11541034","territory":"US","patent_type":null,"expiry_date":"2041-10-31T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-19T23:04:52.906360+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}